Promoting lung healing and preventing scarring
Program to promote lung regeneration and block fibrosis
This study is looking at how lung cells work together to find new treatments for pulmonary fibrosis, and it will test a promising compound called EGCG to see if it can help improve lung health for people with idiopathic pulmonary fibrosis (IPF).
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11032741 on NIH RePORTER |
What this research studies
This research program aims to explore how lung cells interact to develop new treatments for pulmonary fibrosis, a condition that currently lacks effective therapies. The team will investigate the effects of a specific compound, EGCG, which has shown promise in reducing fibrosis in preliminary studies. By understanding the roles of different lung cell types, the researchers hope to enhance lung regeneration and mitigate scarring. The research includes a clinical trial to test the effectiveness of EGCG in patients with idiopathic pulmonary fibrosis (IPF).
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis (IPF) who are experiencing lung scarring.
Not a fit: Patients with other forms of lung disease or those who do not have pulmonary fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve lung function and quality of life for patients with pulmonary fibrosis.
How similar studies have performed: Other research has shown promising results with similar approaches, particularly in targeting fibrosis and enhancing lung regeneration, indicating potential for success in this area.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Chapman, Harold a — University of California, San Francisco
- Study coordinator: Chapman, Harold a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.